Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Koeppen

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Neoplasia (New York, N.Y.)|July 2, 2013
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseDeepak Sampath, Jason Oeh, Shelby K Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2025
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of ImmunotherapyJahlisa S Hooiveld-Noeken, Laura Kist de Ruijter, Pim P van de Donk, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Neoplasia (New York, N.Y.)|July 2, 2013
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseDeepak Sampath, Jason Oeh, Shelby K Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2025
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of ImmunotherapyJahlisa S Hooiveld-Noeken, Laura Kist de Ruijter, Pim P van de Donk, et al.
Pageof 15